Clinical trials: Pleura; Effusion
Hemorrhage, Atrial Fibrillation, Postoperative
Prevention of Retained-Blood Outcomes With Active Clearance Technology
Postoperative bleeding is a common consequence after heart surgery which can significantly impact outcomes and costs . When bleeding occurs, reliable postoperative blood evacuation of the pleural, mediastinal and pericardial…
- Trial name
- NCT02145858
- Testing
- Blood drainage post cardiac surgery using PleuraFlow System
- Where
- 2 sites in United States
- Volunteers
- 891 people
- Sponsor
- ClearFlow, Inc.
Malignant Pleural Effusions
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions
The purpose of this study is to determine whether a new catheter is safe and effective in treating malignant pleural effusions.
- Trial name
- NCT02227732
- Testing
- New Indwelling Pleural Catheter
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- C. R. Bard
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Malignant Pleural Effusions
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over…
- Trial name
- NCT03869697
- Testing
- SCB-313
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Pleural Effusion
Vibration Response Imaging (VRI) in Management and Evaluation in Patients With Pleural Effusion
The primary purpose of this study is evaluate the VRI device's accuracy in diagnosis of pleural effusion (in comparison to chest x-ray and ultrasonography), and to assess the pleural effusion location and size.
- Trial name
- NCT00473291
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Deep Breeze
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
Malignant Pleural Effusions (Mpe)
A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.
- Trial name
- NCT07649369
- Testing
- JMKX000197, Cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer Stage IV
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy.
- Trial name
- NCT02047344
- Testing
- Antroquinonol
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- Golden Biotechnology Corporation
Pleural Effusion, Pleural Effusion, Malignant
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
The goal of this observational study is to learn about the performance of the drainova® ArgentiC Catheter in clinical routine, which is used to treat fluid accumulations in hollow body structures.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Ascites, Ascites, Malignant
- Trial name
- NCT06436807
- Testing
- Indwelling catheter
- Where
- 12 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ewimed GmbH
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Pleural Effusion, Pleural Effusion, Malignant
Multiple Biomarkers in Undiagnosed Pleural Effusion
The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions.
- Trial name
- NCT00316134
- Testing
- Procedure/Surgery
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Malignant Pleural Effusion
Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients
Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion
- Trial name
- NCT02191540
- Testing
- Abnoba Viscum F 20mg
- Where
- 3 sites in South Korea
- Volunteers
- 68 people
- Sponsor
- Abnoba Korea
Malignant Pleural Effusion, Malignant Ascites
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it…
- Trial name
- NCT03736122
- Testing
- BSG-001
- Where
- Australia
- Volunteers
- 58 people
- Sponsor
- BioSyngen Pte Ltd
Metastatic Non-squamous Non Small Cell Lung Cancer
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with…
- Trial name
- CBP08-02 (NCT00942825)
- Testing
- CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 195 people
- Sponsor
- CanBas Co. Ltd.
Pleural Effusion
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
- Trial name
- NCT04159831
- Testing
- LTI-01
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Rein Therapeutics
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Malignant Pleural Effusion
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
The purpose of this study is to determine whether a new catheter is safe and effective in treating malignant pleural effusions compared to approve catheter.
- Trial name
- SWIFT (NCT02649894)
- Testing
- Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter, Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 119 people
- Sponsor
- C. R. Bard
Malignant Pleural Effusion, Lung Cancer
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy.
- Conditions
- Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer
- Trial name
- MpeTK01 (NCT01997190)
- Testing
- AdV-tk + valacyclovir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Candel Therapeutics, Inc.